The availability of effective prophylactic treatments for HAE with anti-Kallikreins such as Lanadelumab or Berotralstat is a groundbreaking improvement in health and quality of life for patients with frequent or severe attacks reducing attack rates by 50–95%. Here, KLK4 is linked to hereditary angioedema.